卵巢癌、输卵管癌和原发性腹膜癌中FRα检测的真实世界分析
本回顾性研究分析425例用VENTANA® FOLR1 RxDx免疫组化检测FRα的样本,高浆液性癌为主。FRα高表达占36.3%,卵巢、输卵管、附件及盆腔优势肿块阳性率44.4%高于转移灶32.5%(p=0.02)。8例多次检测中3例(37.5%)结果不一致。
要点
- FRα高表达见于36.3%的病例,与高级别浆液性卵巢癌组织学显著相关。
- 卵巢、输卵管、附件及盆腔优势肿块FRα阳性率44.4%高于转移灶32.5%(p=0.02)。
- 8例多次检测中3例(37.5%)结果不一致,提示需标准化FRα检测流程。
核心结论
- FRα表达受肿瘤组织学和解剖起源影响,存在异质性,需进一步研究以优化治疗结局。
- 作者认为需要标准化FRα检测方案,以确保不同临床环境下生物标志物评估准确。
研究设计与样本
- 回顾性研究分析425例患者样本,使用VENTANA® FOLR1 RxDx免疫组化检测FRα,队列以高级别浆液性癌为主,样本来自不同解剖部位。
主要发现
- FRα高表达占36.3%,FRα阳性与高级别浆液性卵巢癌组织学显著相关。
- 卵巢、输卵管、附件及盆腔优势肿块样本FRα阳性率44.4%,高于转移灶的32.5%(p=0.02)。
- 样本采集至检测时间不影响FRα表达,检测中位时间为采集后19.5个月。
- 8例患者检测了多个样本,其中3例(37.5%)在后续样本检测时结果不一致。
关键数值与推荐
- FRα高表达定义为VENTANA® FOLR1 RxDx免疫组化检测结果,高表达率为36.3%。
- 卵巢、输卵管、附件及盆腔优势肿块FRα阳性率为44.4%,转移灶为32.5%(p=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and survival outcomes. MIRV targets folate receptor alpha (FRα), a cell-surface receptor that is overexpressed in EOC and has been associated with aggressive disease phenotypes. METHODS: This retrospective study analyzed 425 patient samples tested for FRα using the VENTANA® FOLR1 RxDx immunohistochemical assay. The patient cohort included cases with high grade serous carcinoma predominantly, tested across various anatomical sites. Statistical analysis examined the correlation between FRα positivity and clinical parameters such as tumor site and histology. RESULTS: FRα was highly expressed in 36.3 % of the cases, with a significant association between FRα positivity and high grade serous ovarian histology. Tumor samples from the ovary, fallopian tube, adnexa, and dominant pelvic masses showed higher FRα positivity compared to metastatic sites (positive rates of 44.4 % vs 32.5 %, p = 0.02), highlighting the potential influence of tumor origin on expression of FRα. Time between sample collection and testing did not impact FRα expression, with sample testing spread over a median of 19.5 months post-collection. Eight patients had more than one specimen tested, of which 3 (37.5 %) had discordant results when a subsequent specimen was tested. CONCLUSION: Our results highlight a need for standardized protocols for FRα testing to ensure accurate biomarker evaluation across varied clinical settings. The heterogeneity in FRα expression, influenced by tumor histology and anatomical origin, warrant further investigation to optimize therapeutic outcomes. PRIOR PRESENTATION: Preliminary findings from this study were previously presented in poster format at the Society of Gynecologic Oncology 2024 Annual Metting. We confirm that the submission complies with the journal requirements.
引用
- Previs RA, Strickland KC, Wallen Z, et al. Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2024. PMID: 39631181. doi:10.1016/j.ygyno.2024.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。